GeneBio Systems
Recombinant Human AXL/UFO Protein(Fc Tag)
Recombinant Human AXL/UFO Protein(Fc Tag)
SKU:PDMH100293
Couldn't load pickup availability
Size:100μg
Storage:Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.
Shipping:This product is provided as lyophilized powder which is shipped with ice packs.
Exp date:12 months
Category ID_II:Recombinant Proteins
Category ID_III:Others
Abbreviation:AXL/UFO
Target Synonym:JTK;Tyro;AXL;ARK;JTK11;Tyro7;UFO;AXL oncogene;Tyrosine-protein kinase receptor UFO
Research Areas:Cell Biology;Tags & Cell Markers;Signal Transduction;Cancer
Conjugation:
Target Species:Human
Expression Host:Mammalian
Application:
Fusion tag:C-Fc
UNIProt ID:P30530
Accession:P30530
Background:Axl receptor tyrosine kinase , together with Tyro3 and Mer , constitute the TAM family of receptor tyrosine kinases. In the nervous system , Axl and its ligand Growth-arrest-specific protein 6 (Gas6) are expressed on multiple cell types. Axl functions in dampening the immune response , regulating cytokine secretion , clearing apoptotic cells and debris , and maintaining cell survival. Axl is upregulated in various disease states , such as in the cuprizone toxicity-induced model of demyelination and in multiple sclerosis (MS) lesions , suggesting that it plays a role in disease pathogenesis. Axl expression correlates with poor prognosis in several cancers. Axl mediates multiple oncogenic phenotypes and activation of these RTKs constitutes a mechanism of chemoresistance in a variety of solid tumors. Axl contributes to cell survival , migration , invasion , metastasis and chemosensitivity justify further investigation of Axl as novel therapeutic targets in cancer. The receptor tyrosine kinase AXL is thought to play a role in metastasis. The soluble AXL receptor as a therapeutic candidate agent for treatment of metastatic ovarian cancer. GAS6/AXL targeting as an effective strategy for inhibition of metastatic tumor progression in vivo.
Concentration:
Activity:Not validated for activity
Sequence:Ala26–Trp451
Purity: > 90% as determined by reducing SDS-PAGE.
Formulation:Lyophilized from a 0.2 μm filtered solution in PBS with 5% Trehalose and 5% Mannitol.
Reconstitution:It is recommended that sterile water be added to the vial to prepare a stock solution of 0.5 mg/mL. Concentration is measured by UV-Vis.
Endotoxin:< 1.0 EU/mg of the protein as determined by the LAL method.
Calculated MW:71.7 kDa
ObservedMW:90-100 kDa
